Department of Nephrology, Meram School of Medicine, Selcuk University, Meram, Konya, Turkey.
Ren Fail. 2011;33(3):307-11. doi: 10.3109/0886022X.2011.560404.
Both erythropoiesis-stimulating agents and iron treatments are underutilized in peritoneal dialysis (PD) patients. Studies to evaluate safety profiles of various intravenous iron preparations are limited in PD patients compared to hemodialysis. No study in the literature compared safety of low-molecular-weight iron dextran (LMW-ID) with that of iron sucrose in PD patients. We aimed to compare adverse-effect profiles of LMW-ID and iron sucrose with varying dosing schedules in PD patients with a hope to foster use of parenteral iron solutions in PD patients.
We retrospectively reviewed patient charts and included patients who were administered iron sucrose or LMW-ID parenterally. Sociodemographic characteristics, clinical features, and pertinent laboratory data were collected. Adverse events which were deemed to be related to infusion of parenteral iron were recorded. We double-checked both physician records and nursing documents for observed adverse events.
A total of 167 chronic PD patients were included in the study, and 92 patients were administered LMW-ID, whereas 75 patients were administered iron sucrose. Only one adverse event occurred in a patient who was administered 500 mg iron sucrose in a single infusion.
This study showed the comparable safety of LMW-ID in varying doses over that of iron sucrose in PD patients.
促红细胞生成素刺激剂和铁剂在腹膜透析（PD）患者中的应用不足。与血液透析相比，用于评估各种静脉内铁制剂安全性的研究在 PD 患者中受到限制。在文献中，没有研究比较低分子右旋糖酐铁（LMW-ID）与蔗糖铁在 PD 患者中的安全性。我们旨在比较 LMW-ID 和蔗糖铁在不同剂量方案下在 PD 患者中的不良效应谱，以期促进 PD 患者使用肠外铁溶液。
我们回顾性地审查了患者的图表，并纳入了接受蔗糖铁或 LMW-ID 肠外给药的患者。收集了社会人口统计学特征、临床特征和相关实验室数据。记录被认为与输注肠外铁有关的不良事件。我们仔细检查了医生记录和护理文件中观察到的不良事件。
本研究共纳入 167 例慢性 PD 患者，92 例患者接受 LMW-ID 治疗，75 例患者接受蔗糖铁治疗。只有一名患者在单次输注中接受 500mg 蔗糖铁时发生了 1 例不良事件。
本研究表明，在 PD 患者中，LMW-ID 在不同剂量下的安全性与蔗糖铁相当。
